L. Rossouw

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

B. Chi, D. Moodley, G. Theron, 2022, BMC Infectious Diseases.

Outcomes of laboratory‐confirmed SARS‐CoV‐2 infection in the Omicron‐driven fourth wave compared with previous waves in the Western Cape Province, South Africa

M. Mendelson, H. Mahomed, R. Kassanjee, 2022, medRxiv.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. Madhi, A. Sigal, T. de Oliveira, 2021, The New England Journal of Medicine.

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

S. Madhi, S. Richardson, P. Moore, 2022, The Lancet Infectious Diseases.

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa

S. Madhi, A. Sigal, T. de Oliveira, 2021, medRxiv.